Brind.

Trinity Biotech's CGM+ aims to lower costs.

1 report, 1 independent Updated Aug 15

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Dexcom BioTech

Keep exploring

The entities involved

Dexcom
company that develops, manufactures and distributes continuous glucose monitoring systems
- Tandem Mobi utilizes Dexcom G7 technology for monitoring.Mon 09:18
- Oura announces partnerships with Dexcom and Resmed for health feature integration, while noting that regulatory uncertainty affects its product scope.Wed 08:52
BioTech
company in Prague, Czechia
- PDS Biotechnology and the National Cancer Institute entered into a collaborative R&D agreement.Sun 13:48

Coverage

Newest first; wire copies grouped

Aug 15ZacksTrinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data Trinity Biotech plc TRIB announced compelling positive clinical trial results with respect to its next-generation continuous gluco